Enodia Therapeutics
Enodia Therapeutics is a biotechnology company developing small-molecule therapies that enable targeted degradation of disease-driving proteins at the point of synthesis. The company’s platform integrates proteomics, machine-learning–enabled selectivity and structural validation to modulate the SEC61 translocon and target secreted and membrane proteins across inflammatory, autoimmune, oncology and infectious disease indications.
Leadership & Board
- Current Number of Employees
- 15
- Current LinkedIn Followers
- 2,162
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $21M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $21M
- Latest Funding Round
- Seed Round
- Post-Money Valuation
- ―
Employee Trend
Enodia Therapeutics had 15 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Enodia Therapeutics had 2,162 followers as of October 12, 2026. The number of followers increased by 115 (5.62%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 08, 2026 | Seed Round | $20.70M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Bpifrance | Seed Round |
| Investsud | Seed Round |
| Sambrinvest | Seed Round |
| Pfizer Ventures | Seed Round |
| Elaia | Seed Round |
| Mission BioCapital | Seed Round |
| Argobio Studio | Seed Round |
| Wallonie Entreprendre | Seed Round |
Similar Companies
A snapshot of private companies similar to Enodia Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
